Cohort Profile: The Japan Diabetes Complications Study: A Long-Term Follow-Up of A Randomised Lifestyle Intervention Study of Type 2 Diabetes
Cohort Profile: The Japan Diabetes Complications Study: A Long-Term Follow-Up of A Randomised Lifestyle Intervention Study of Type 2 Diabetes
The Author 2013; all rights reserved. Advance Access publication 18 May 2013
COHORT PROFILE
Department of Clinical Trial Design and Management, Translational Research Center, Kyoto University Hospital, Kyoto, Japan,
EBM Research Center, Kyoto University Graduate School of Medicine, Kyoto, Japan, 3Department of Biostatistics, School of Public
Health, University of Tokyo, Tokyo, Japan, 4Department of Ophthalmology, Yamagata University Faculty of Medicine, Yamagata,
Japan, 5Department of Endocrinology and Diabetes, School of Medicine, Saitama Medical University, Saitama, Japan, 6Institute for
Adult Diseases, Asahi Life Foundation, Tokyo, Japan, 7Department of Internal Medicine, University of Tsukuba Institute of Clinical
Medicine, Tsukuba, Ibaraki, Japan and 8Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan
*Corresponding author. Department of Internal Medicine, Niigata University Faculty of Medicine, 1-757 Asahimachi-dori, Chuoh-ku,
Niigata, 951-8510, Japan E-mail: [email protected]
Accepted
11 March 2013
The Japan Diabetes Complications Study, a randomised lifestyle
intervention study of type 2 diabetes conducted at 59 institutes
throughout Japan that enrolled 2033 eligible patients from
January 1995 to March 1996, was directed at: (i) determining the
incidence and progression rates of complications of diabetes; (ii)
exploring clinical risk factors for complications of diabetes; and
(iii) determining the association between lifestyle factors, including
diet and physical activity, and complications of diabetes, in addition
to comparing, in a randomised manner, the effects on type 2 diabetes of an extensive lifestyle intervention and conventional treatment. The protocol for the study originally specified four study
populations according to primary outcomes, consisting of: (1) a
macroangiopathy group (N 1771); (ii) a nephropathy group
(N 1607); (iii) a retinopathy-incident group (N 1221); and (iv)
a retinopathy-progression group (N 410). The primary outcomes
were: (i) development of retinopathy; (ii) progression of retinopathy; (iii) development of overt nephropathy; and (iv) occurrence of
macroangiopathic events including proven coronary heart disease
and stroke. The study was originally planned to follow patients
for 8 years, and an extended follow-up is ongoing. Information
about primary outcomes, laboratory tests, and other clinical variables for each patient was collected at a central data centre through
an annual report from each investigator. Additionally, extensive
lifestyle surveys were conducted at baseline and 5 years after the
beginning of the study intervention in both the intervention and
conventional treatment groups. A description of the occurrence of
complications of diabetes and of all-cause mortality, provided in
this paper, demonstrated a clear gender-based difference in
1054
1055
1056
University hospital
General hospital
Figure 1 Outpatient clinics at 59 university and general hospitals nationwide in Japan that specialise in diabetes care
level < 220 mg/dL, serum triglyceride level < 150 mg/dL,
serum high-density lipoprotein (HDL) cholesterol440 mg/dL, waist-to-hip ratio < 0.9 for men
and < 0.8 for women, smoking cessation, and abstinence from alcohol. The goals for BP and serum cholesterol levels were updated in accordance with the
revision of guidelines made by the Japan Diabetes
Society (JDS), which were < 130/80 mmHg and
< 220 mg/dL, respectively.
The protocol for the JDCS originally specified four
analysis populations according to primary outcomes
(Figure 2). The macroangiopathy group consisted of
1771 patients after the exclusion of patients with a
history of angina pectoris, myocardial infarction,
stroke, peripheral arterial disease, familial hypercholesterolaemia, or type III hyperlipidaemia. The nephropathy group was originally defined as the analysis
population for incident overt nephropathy among
patients with normo or low microalbuminuria. This
analysis population consisted of 1558 patients after
the exclusion of those with non-diabetic nephropathy,
nephrotic syndrome, serum creatinine levels
4120 mmol/L, or a mean value of two spot urine examinations that showed an albumin excretion rate of
<150 mg/g creatinine.12 In future analyses, in which
incident overt nephropathy from high microalbuminuria can be of secondary interest, we plan to
extend the nephropathy group by including 49
N = 16
Not included in any groups
(N = 54)
N = 167
N = 158
N = 1266
N = 25
N = 174
N = 173
Macroangiopathy group
(N = 1771)
1057
Retinopathy-incident and
retinopathy-progression groups
(N = 1221 + 410)
Primary outcomes
Primary outcomes of the JDCS consisted of microand macro-vascular complications. Retinopathy was
evaluated by qualified ophthalmologists at each participating institution, using the classification designed
for this research, as follows: (i) stage 0, no retinopathy; (ii) stage 1, haemorrhage and hard exudates;
(iii) stage 2, soft exudates; (iv) stage 3, intraretinal
microvascular abnormalities and venous changes
including beading, loops, and duplication; and (v)
stage 4, new vessels, vitreous haemorrhage, fibrous
proliferation, and retinal detachment. The retinopathy
endpoints were; (i) development of retinopathy (from
stage 0 to any other stage confirmed in two continuous years); and (ii) progression from stage 1 to stage
3 or 4. The nephropathy endpoint was defined as the
development of overt nephropathy (spot urinary albumin excretion 4300 mg/g creatinine in two consecutive samples). Macroangiopathy endpoints included
the incidence of definite coronary heart disease
(angina pectoris or myocardial infarction) or stroke.
Diagnosis of angina pectoris and myocardial infarction was made according to criteria defined by the
WHO/ Multinational Monitoring of Trends and
Determinants in Cardiovascular Disease (MONICA)
project, and diagnosis of stroke was made according
to guidelines defined by the Ministry of Health,
Labour and Welfare of Japan.13 Adjudication of endpoints was done by central committees consisting of
experts in each complication, on the basis of additional data such as findings on computed tomography (CT) or magnetic resonance imaging (MRI) of
the brain or sequential changes in electrocardiograms.
Dietary survey
Food Frequency Questionnaires based on food groups
(FFQg)14 and 24-hour dietary records were collected at
baseline and 5 years after the beginning of the study
intervention from both the intervention and conventional treatment groups. In brief, the FFQg consists
of items about 29 food groups and 10 kinds of cookery
and elicits information about the average intake per
week of each food or food groups in commonly used
units or portion sizes. The FFQg was externally validated through a comparison with weighed dietary records for 7 continuous days of 66 subjects aged 1960
years.14 The coefficients of correlation of the FFQg with
1058
No. unretrieved
case records
Year 1 13
Year 2 40
Year 3 40
Year 4 47
Year 5 28
Year 6 58
Year 7 33
Year 8 50
Control group
N = 1016
Intervention group
N = 1017
No. unretrieved
case records
Year 1 10
Year 2 24
Year 3 29
Year 4 31
Year 5 35
Year 6 52
Year 7 28
Year 8 33
Table 1 Comparison of baseline characteristic of patients in the entire cohort, those with no baseline dietary data, and
those not followed for 8 years
Men in the entire
cohort
(N 1087)
Age (year)
HbA1c (%)
Mean
58.1
SD
7.0
Women in the
entire cohort
(N 946)
No baseline
dietary data
(N 445)
Not followed
for 8 years
(N 551)
Mean
59.0
Mean
57.9
Mean
58.4
SD
6.8
SD
7.1
SD
7.1
7.7
1.2
8.1
1.4
7.8
1.2
8.0
1.4
158.9
41.4
161.3
45.4
158.6
42.8
164.1
45.4
11.5
7.7
10.2
6.6
10.7
7.7
10.8
7.6
19.0%
Weight (kg)
62.5
8.8
54.4
8.3
59.9
10.0
59.0
9.5
BMI (kg/m2)
22.8
2.7
23.3
3.4
23.4
3.2
23.1
3.0
82.3
7.8
76.6
9.6
80.5
9.6
80.1
9.1
Waist-to-hip ratio
0.89
21.5%
0.06
0.84
13.0%
0.07
0.88
17.2%
0.08
0.87
0.08
SBP (mmHg)
131.1
15.7
132.4
16.9
131.7
16.8
131.2
15.9
DBP (mmHg)
77.3
9.9
76.3
10.1
77.4
10.2
76.9
9.5
194.5
34.5
209.4
33.7
203.9
35.1
202.8
36.2
LDL-C (mg/dL)
116.7
32.5
129.2
30.9
123.2
32.7
124.1
33.4
HDL-C (mg/dL)
Triglyceridesa (mg/dL)
52.3
16.5
57.2
16.7
54.5
16.2
54.4
16.8
130.2
85.4
99.0
71.0
109.0
87.0
104.0
69.0
LP(a)a (mg/dL)
22.8
27.2
17.0
19.6
17.0
19.8
16.0
21.0
60.6
271.3
18.5
31.6
20.2
44.0
20.4
41.5
eGFR (mL/min/1.73m2)
85.3
28.5
88.6
29.2
85.0
24.8
87.6
27.5
19.5%
22.5%
21.9%
17.7%
64.2%
66.7%
64.5%
65.7%
22.4%
32.8%
28.2%
27.1%
16.7%
35.1%
27.8%
24.4%
44.7%
8.8%
26.7%
31.6%
Abbreviations: ACR: albumin-to-creatinine ratio; BMI: body mass index; DBP: diastolic blood pressure; eGFR: estimated glomerular
filtration rate; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Lp(a): lipoprotein(a); OHA:
oral hypoglycemic agents; SBP: systolic blood pressure.
a
Median and interquartile range.
1059
1060
Other publications
In addition to reporting its primary results,10 the
JDCS reported the pathophysiological characteristics
of East Asian patients with type 2 diabetes.2225 In a
3-year interim report, we found small but significant
differences in HbA1c levels in the intervention group
(7.62 1.20%) and conventional therapy group
(7.78 1.27%) that had appeared as early as 2 years
after the beginning of the intervention in the JDCS
Table 2 Crude incidence rates of diabetes complications and all-cause mortality over 8 years
Total
Incident retinopathy
Progression of retinopathy
Men
Women
N
1221
Event
325
CIR
38.27
N
671
Event
165
CIR
34.77
N
550
Event
160
CIR
42.70
410
65
13.88
207
28
17.03
203
37
10.47
Overt nephropathy
1607
96
8.48
842
56
9.47
765
40
7.40
Cardiovascular disease
1771
163
21.09
940
104
17.65
831
59
24.75
All-cause mortality
2033
98
7.11
1087
61
8.39
946
37
5.68
Background characteristics
Baseline (1995)
ADC
ADC
ADC
ADC
ADC
Chest radiographs
ADC
ADC
ADC
ADC
Neurological examination
ADC
ADC
ADC
ADC
Urine testsb
ADC
ADC
ADC
ADC
Ophthalmological examination
ADC
ADC
ADC
ADC
Therapeutic measures
ADC
ADC
ADC
ADC
Electrocardiograms
ADC
ADC
ADC
ADC
Cardiovascular events
ADC
ADC
ADC
ADC
Lifestyle surveys
ADC
ADC
1061
Funding
The JDCS is financially supported by the Ministry of
Health, Labour and Welfare, Japan.
Conflict of interest: None declared.
KEY MESSAGES
This study of 2033 Japanese patients with type 2 diabetes was originally established in 1995 as a
randomised lifestyle intervention trial. Its analysis of primary data at 8 years revealed a significant
effect of the intervention used in the study on the incidence of stroke but not of other macro- or
microvascular complications of diabetes.
The study also aimed to explore epidemiological associations of clinical risk factors for diabetes, of
lifestyle factors with the complications of diabetes, and of complications of diabetes themselves.
Extensive lifestyle surveys, including surveys of diet and physical activity, were done at baseline
and at 5 years, and an extended follow-up is ongoing.
Little is known about the effects of lifestyle factors on the prognosis of Asian patients with type 2
diabetes characterised by low body weight. Comparing our cohort, which is representative of
Japanese patients type 2 diabetes, with studies of Caucasian patients should provide further insights
into ethnic disparities in this disease.
References
1
10
1062
11
12
13
14
15
16
17
18
19
20
21
with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications
Study). Diabetologia 2010;53:41928.
The Japan Diabetes Society. Food Exchange Lists Dietary
Guidance for Persons with Diabetes. Tokyo: Bunkodo, 2002.
Katayama S, Moriya T, Tanaka S et al. for the Japan
Diabetes Complications Study Group. Low transition
rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals: the Japan
Diabetes Complications Study (JDCS). Diabetologia 2011;
54:102531.
Sone H, Katagiri A, Ishibashi S et al. JDC Study Group.
Effects of lifestyle modifications on patients with type 2
diabetes: the Japan Diabetes Complications Study (JDCS)
study design, baseline analysis and three-year interim
report. Horm Metab Res 2002;34:50915.
Takahashi K, Yoshimura Y, Kaimoto T et al. Validation of
a food frequency questionnaire based on food groups for
estimating individual nutrient intake. Jpn J Nutr 2001;59:
22132.
Ministry of Education C, Sports, Science and Technology,
Japan. Standard Tables of Food Composition in Japan
2004. http://www.mextgojp/b_menu/shingi/gijyutu/gijyutu3/
toushin/05031802htm (in Japanese), accessed 7 Oct 2011.
Tanasescu M, Leitzmann MF, Rimm EB, Hu FB. Physical
activity in relation to cardiovascular disease and total
mortality among men with type 2 diabetes. Circulation
2003;107:243539.
Ainsworth BE, Haskell WL, Herrmann SD et al. 2011
Compendium of Physical Activities: a second update of
codes and MET values. Med Sci Sports Exerc 2011;43:
157581.
The Statistics Bureau and the Director-General for
Policy Planning of Japan MoIAaC. Japan Standard
Classification of Occupations. http://www.statgojp/index/
seido/shokgyou/indexhtm. 1997 (in Japanese).
Ministry of Health Law. Japan National Health and
Nutrition Survey. http://www.mhlwgojp/bunya/kenkou/
kenkou_eiyou_chousahtml. 2010 (in Japanese).
Baecke JA, Burema J, Frijters JE. A short questionnaire
for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr 1982;36:93642.
The Committee on the Standardization of Diabetes
Mellitus-Related Laboratory Testing of Japan Diabetes
22
23
24
25
26
27
28
Society. International clinical harmonization of hemoglobin A1c in Japan: From JDS to NGSP values. Available
from http://www.jds.or.jp/jds_or_jp0/uploads/photos/813.
pdf (20 June 2012, date last accssed).
Sone H, Yoshimura Y, Ito H, Ohashi Y, Yamada N. Japan
Diabetes Complications Study Group. Energy intake and
obesity in Japanese patients with type 2 diabetes. Lancet
2004;363:24849.
Sone H, Mizuno S, Fujii H et al. Japan Diabetes
Complications Study. Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in
Asian diabetic patients? Analysis from the Japan
Diabetes Complications Study. Diabetes Care 2005;28:
146371.
Sone H, Tanaka S, Ishibashi S et al. Japan Diabetes
Complications Study (JDCS) Group. The new worldwide
definition of metabolic syndrome is not a better diagnostic predictor of cardiovascular disease in Japanese diabetic patients than the existing definitions: additional
analysis from the Japan Diabetes Complications Study.
Diabetes Care 2006;29:14547.
Sone H, Tanaka S, Iimuro S et al. Waist circumference as
a cardiovascular and metabolic risk in Japanese patients
with type 2 diabetes. Obesity 2009;17:58592.
Kawasaki R, Tanaka S, Tanaka S et al. on behalf of the
Japan Diabetes Complications Study Group. Incidence
and progression of diabetic retinopathy in Japanese
adults with type 2 diabetes: 8 year follow-up study of
the Japan Diabetes Complications Study (JDCS).
Diabetologia 2011;54:228894.
Sone H, Tanaka S, Tanaka S et al. for the Japan Diabetes
Complications Study Group. Serum level of triglycerides
is a potent risk factor comparable to LDL cholesterol for
coronary heart disease in Japanese patients with type 2
diabetes:
Subanalysis
of
the
Japan
Diabetes
Complications Study (JDCS). J Clin Endocrinol Metab
2011;96:344856.
Sone H, Tanaka S, Tanaka S et al. on behalf of the Japan
Diabetes Complications Study Group. Comparison of various lipid variables as predictors of coronary heart disease
in Japanese men and women with type 2 diabetes.
Subanalysis of the Japan Diabetes Complications Study
(JDCS). Diabetes Care 2012;35:115057.